CGM

Veri Releases New Metabolic Health Program

Retrieved on: 
Thursday, January 11, 2024
Biomarker, Science, CGM, Glucose, Habit, Health, Harvard University, Medical device

HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.

Key Points: 
  • HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.
  • Built by Veri's health team in coordination with advisors from Stanford, Duke, and Harvard, the new four-stage program gives members a personalized metabolic health coach in their pocket:
    Daily guidance to help members understand their metabolic health, glucose levels, and how to make improvements.
  • "At Veri, we believe that every person holds the power to achieve optimal metabolic health through sustainable lifestyle change," said Dr. Vimal Ramjee, Director of Heath at Veri.
  • "With that in mind, we created The Veri Program, a personalized four-stage experience that puts your glucose data into context with your lifestyle to deliver impactful, evidence-based action steps that improve metabolic health."

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Retrieved on: 
Monday, January 8, 2024
Software, Mobile, Wireless, General Health, Hardware, Consumer Electronics, Medical Devices, Technology, Health Technology, Wearables, Mobile Technology, FDA, Health, Diabetes, Stelo, Eastern Time Zone, CGM, International, Diet, Insulin, DXCM, Dexcom, Sleep, Growth, Acceleration, Exercise, Pharmaceutical industry

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.
  • U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022.
  • For fiscal 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022.
  • “Through our expanding product portfolio, Dexcom is defining the future of sensing technology and empowering people to take control of health.”
    Dexcom will report its audited full fourth quarter and fiscal 2023 financial results on Thursday, February 8, 2024 after the close of market.

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Retrieved on: 
Monday, January 8, 2024
Wearables, Mobile Technology, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biotechnology, Health, Continuous glucose monitor, Personal, Multimedia, CGM, Caregiver, DME, AID, Disease, Hyperglycemia, Internet, Tandem Diabetes Care, Control, FreeStyle, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
  • View the full release here: https://www.businesswire.com/news/home/20240108667517/en/
    t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States.
  • (Photo: Business Wire)
    Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump.
  • FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump.

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Retrieved on: 
Monday, January 8, 2024
Medtronic, Meal, CGM, IOS, FDA, Insulin, Diabetes, CE marking, Hyperglycemia, CE, Outline of health sciences, Android, Snack, EVP, Medical device

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.*  

Key Points: 
  • Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.
  • *
    The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024.
  • Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor.
  • With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes.

Nuvilab Innovates Inpatient Nutrition with Food AI at Alexandra Hospital Singapore

Retrieved on: 
Friday, January 5, 2024
Patient, Multimedia, CGM, Collection, Digital health, ICT, Diet, Nutrient, Diabetes, Alexandra Hospital, Hospital, Las Vegas Convention Center, LVCC, Child, CES, Bed, Glucose meter

SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital.

Key Points: 
  • SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital.
  • This solution uses an AI Food Scanner to scan each patient's meal tray and analyze individual food intake and nutrients.
  • The system was first tested at Alexandra Hospital in Singapore, where it underwent a seven-week pilot phase to showcase technological advancements in healthcare.
  • Following the successful trial period, Alexandra Hospital recently formalized an agreement with Nuvilab to implement their solution for inpatient care.

Senseonics Holdings, Inc. Announces Business Updates

Retrieved on: 
Tuesday, January 2, 2024
Diabetes, Health Technology, Health, Medical Devices, Gemini, PHC, Marketing, CGM, FDA, Doctor of Philosophy, DTC, Growth, Calibration, Pharmaceutical industry

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates.
  • Significant new lead generation from advertising campaign activities in the fourth quarter by our global commercial partner Ascensia Diabetes Care demonstrated strong patient response to the Eversense message.
  • Now Ascensia is working to accelerate and improve the conversion of those leads by enhancing its CGM-dedicated commercial infrastructure,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
  • The Company expects to report its full fourth quarter and fiscal year 2023 financial results in the ordinary course later this quarter.

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Retrieved on: 
Tuesday, January 2, 2024
Clutch (eggs), CGM, Diabetes, Blood, Doctor of Philosophy, MARD, Glucose, Longevity, Calibration, Medical device

The Company announces the successful completion of their first preclinical study of the implantable CBGM.

Key Points: 
  • The Company announces the successful completion of their first preclinical study of the implantable CBGM.
  • In comparison, many continuous glucose monitoring (CGM) systems measure glucose in the interstitial fluid, which lags behind blood glucose.
  • The Company also announces a second milestone: the commencement of long-term preclinical testing on the implantable CBGM.
  • GlucoTrack is committed to commercializing an implantable CBGM with a long-term sensor life, no requirement for an additional wearable component, and a once-only calibration event.

EQS-News: CGM continues to drive digitization in healthcare and reports 10 % revenue growth in first nine months

Retrieved on: 
Saturday, December 30, 2023
Health, CGM, Physician, Hospital, AI, Traction, Limited partnership, Pharmacy, Growth, EUR, Patient, Intelligence, Medical device

CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023.

Key Points: 
  • CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023.
  • Together with the gematik, CGM has supported its customers – doctors, hospitals and pharmacies – in the third quarter to drive the usage of e-Prescriptions for the benefit of patients.
  • The German governmental initiative for the modernization and digitization of hospitals is a key growth driver in CGM's hospital information systems segment.
  • Also, CGM is increasingly providing clinical rehab customers with connectivity solutions, thereby laying the foundation for further digitization measures.

PharmaSens Successfully Submits FDA Approval Application for Groundbreaking Insulin Pump System

Retrieved on: 
Saturday, December 30, 2023
FDA, ISO, Patient, Partnership, Sale, Diabetes, CGM, Certification, Medical device

FDA application for the 'niia essential' marks a major milestone in advancing insulin pump technology with its innovative, patient-centric design

Key Points: 
  • FDA application for the 'niia essential' marks a major milestone in advancing insulin pump technology with its innovative, patient-centric design
    'niia essential' Insulin Patch Pump System targets the significant yet underserved 'almost pumpers' market, tapping into an estimated $10 billion opportunity
    Engaging in strategic financial discussions, PharmaSens prepares for a dynamic market entry and continuous development in diabetes care technology
    PharmaSens AG, a privately owned Swiss company dedicated to expanding access to insulin pump therapy, today announced the successful and timely submission of its application for FDA approval for the revolutionary "niia essential" insulin pump system.
  • Marcel Both, CEO of PharmaSens, stated, "Our submission to the FDA is a pivotal step towards making advanced diabetes care accessible.
  • With a robust patent portfolio and a seasoned team, PharmaSens is well-positioned to meet the stringent requirements of the FDA.
  • "As we anticipate a favorable review from the FDA, PharmaSens is gearing up for the market launch of our 'niia essential' insulin pump system.

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Retrieved on: 
Saturday, December 23, 2023
Food, Priority review, CGM, Symantec Endpoint Protection, FDA, NDA, New Drug Application, Congenital hyperinsulinism, Part, CRL, Patient, Safety, Hypoglycemia, Pharmaceutical industry

The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon.

Key Points: 
  • The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon.
  • The CRL is related to deficiencies identified following an inspection at a third-party contract manufacturing facility.
  • The FDA granted dasiglucagon Priority Review on August 30, 2023 for up to three weeks of dosing.
  • Part 1 relates to dosing of up to 3 weeks and Part 2 relates to the use beyond 3 weeks.